Critical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC

Similar documents
Controversies in the management of Non-muscle invasive bladder cancer

Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer

Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC

Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

Risk Adapted Treatment of Non-muscle Invasive Bladder Cancer. Eila C. Skinner, MD

Management options for high-risk, BCG-refractory NMIBC. Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

Management of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS

A rational risk assessment for intravesical recurrence in primary low grade Ta bladder cancer: A retrospective analysis of 245 cases

THE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER

The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland

Non-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience. Paul Gellhaus Assistant Clinical Professor

Optimising the management of non-muscle invasive bladder cancer from diagnosis to cure. Dr Richard Savdie Uro-Oncology Fellow BSc MBBS FRACS

Review Article. Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer

T1HG Bladder Cancer What is the Best Therapy?

BCG Failure or BCG Unresponsive: Defining and Managing Difficult Patients

Objectives. Results. Patients and Methods. Conclusions. associated percentages were used to analyse treatment variables.

Original Article APMC-276

MANAGING PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: OLD DISEASE, NEW IDEAS

Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk Non-muscle-invasive

Clinical Practice Recommendations for the Management of Non Muscle Invasive Bladder Cancer

Intravesical Therapy for Bladder Cancer

Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.

Contents of Online Supporting Information. etable 1. Study characteristics for trials of intravesical therapy vs. TURBT alone

Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome

The value of EORTC risk tables in evaluating recurrent non muscle invasive bladder cancer in everyday practice

Non-muscle invasive bladder cancer: Are epicrises the Bermuda Triangle of information transfer?

Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer

Reviewing Immunotherapy for Bladder Carcinoma In Situ

EUROPEAN UROLOGY 56 (2009)

14th Meeting of the EAU Section of Oncological Urology (ESOU)

Update on bladder cancer diagnosis and management

Kyung Won Seo, Byung Hoon Kim, Choal Hee Park, Chun Il Kim, Hyuk Soo Chang

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Frequency and predictors of recurrence of bladder tumour on first check cystoscopy a tertiary care hospital experience

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non Muscle-Invasive Bladder Cancer

Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure

/05/ /0 Vol. 174, 86 92, July 2005 THE JOURNAL OF UROLOGY. Printed in U.S.A. Copyright 2005 by AMERICAN UROLOGICAL ASSOCIATION

HOW TO USE HEXVIX. A practical guide for preparation of Hexvix

Second transurethral resection against Ta high grade tumor:residual location and predictive factor. A single center, retrospective study

Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

Diagnosis & Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guidelines

Issues in the Management of High Risk Superficial Bladder Cancer

Urological Oncology INTRODUCTION. M Hammad Ather, Masooma Zaidi

BCG Unresponsive NMIBC: What s Available?

CAN INTRAVESICAL BACILLUS CALMETTE-GUÉRIN REDUCE RECURRENCE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER? A META-ANALYSIS OF RANDOMIZED TRIALS

CUA guidelines on the management of non-muscle invasive bladder cancer

CUA guidelines on the management of non-muscle invasive bladder cancer

Early radical cystectomy in NMIBC Marko Babjuk

Research Report. Keywords: Bladder Cancer, BCG failure, virtual clinical trial, mitomycin C

Improving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression in Superficial Bladder Cancer

Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)

Phase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer

Effectiveness of A Single Immediate Mitomycin C Instillation in Patients with Low Risk Superficial Bladder Cancer: Short and Long-Term Follow-up

Citation for published version (APA): Cauberg, E. C. C. (2011). Advancements in diagnostic imaging for urothelial carcinoma.

Radical Cystectomy Often Too Late? Yes, But...

Role of Re-Resection in Non Muscle-Invasive Bladder Cancer

ONCOLOGY LETTERS 11: , 2016

Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a

european urology 52 (2007)

The outcome of non-muscle invasive urinary bladder tumour at Makassed General Hospital

SUPERFICIAL BLADDER CANCER MANAGEMENT

UC San Francisco UC San Francisco Previously Published Works

Rianne J.M. Lammers*, Joan Palou, Wim P.J. Witjes*, Maria H.D. Janzing-Pastors, Christien T.M. Caris and J. Alfred Witjes* Objective

Contemporary management of high-grade T1 bladder cancer Arnulf Stenzl

Next-generation sequencing in non-muscle-invasive bladder cancer a step towards personalized medicine for a superficial bladder tumor

imedpub Journals

UROTHELIAL CELL CANCER

RESEARCH ARTICLE. Abstract. Introduction. Patients and Methods

Initial experience of partial cystectomy with transurethral laparoscopic technique for bladder carcinoma.

Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression

Old and New Radiation for Bladder and Upper Tract Cancers. Bridget Koontz Radiation Oncology Duke Cancer Institute

Effect of internal iliac artery chemotherapy after transurethral resection of bladder tumor for muscle invasive bladder cancer

Effective Health Care Program

Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015

Harry W. Herr and S. Machele Donat Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Urinary Bladder Cancer

Novel therapeutic strategies for NMIBC. Peter Black Vancouver Prostate Centre University of British Columbia

INTRAVESICAL THERAPY AND FOLLOW-UP OF SUPERFICIAL TRANSITIONAL CELL CARCINOMA OF THE BLADDER

The Role of Bacillus Calmette-Guérin in the Treatment of Non Muscle-Invasive Bladder Cancer

Management of Superficial Bladder Cancer Douglas S. Scherr, M.D.

Preoperative neutrophil to lymphocyte ratio improves recurrence prediction of non-muscle invasive bladder cancer

September 10, Dear Dr. Clark,

ICUD-EAU International Consultation on Bladder Cancer 2012: Non Muscle-Invasive Urothelial Carcinoma of the Bladder

Ivyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract

RITE Thermochemotherapy in the treatment of BCG refractory NMIBC

The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis

Disclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility

Recurrence and Progression of Disease in Non Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy

Abstract. Abstract. Abstract. Abstract. Abstract 11/12/2013. Contemporary Intravesical Therapy for Non-Muscle Invasive Bladder Cancer

RAPN. in T1b Renal Masses? A. Mottrie. G. Denaeyer, P. Schatteman, G. Novara

UC San Francisco UC San Francisco Previously Published Works

NEW HOPE IN BLADDER CANCER TREATMENT



EAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER

Symptoms of Bacillus Calmette-Guerin Cystitis in Bladder Cancer Patients according to Tuberculosis Sequelae by Chest Radiography

Research Project Plan RP Barcelona 2010

Treatment of Invasive Bladder Cancer in the Elderly and Frail Pa9ent

Transcription:

Critical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC Levent N. Türkeri MD, PhD Professor of Urology Acıbadem University Faculty of Medicine Istanbul

Conflict of Interest No relevant COI For this presentation

Risk Stratification Recurrence and Progression Risk 1 Recurrence (%)* Progression (%)** Risk Group 1 year 5 year 1 year 5 year Low 15 31 0.2 0.8 Intermediate 24-38 46-62 1-5 6-17 High 61 78 17 45 Recurrence Risk* Low risk = EORTC recurrence score 0 Intermediate risk = EORTC recurrence score 1-9 High risk = EORTC recurrence score 10-17 Progression Risk** Low risk = EORTC recurrence score 0 Intermediate risk = EORTC recurrence score 2-13 High risk = EORTC recurrence score 14-23 EORTC: European Organisation for Research and Treatment of Cancer 1. Babjuk M et al. Guidelines on non-muscle invasive bladder cancer. EAU March 2011.

Early Single Dose Instillation 1 Group Recurrence Rate % Change p value TUR alone 48.4% TUR + SI 36.7% 11.7% <0.0001 Single tm TUR alone 47.1% TUR + SI 35.8% 11.3% 0.0005 Multiple tm TUR alone 81.5% TUR + SI 65.2% 16.3% 0.06 tm: tumour TUR: Transurethral resection SI: Single instillation 1. Sylvester RJ et al. J Urol 2004; 171: 2186-90.

Early Single Dose Instillation 1 Forest Plot of Recurrence by Treatment Study Publ Year Treatment Events/Patients Statistics OR & Cl (1-OR) TUR Alone TUR+Chemo (O-E) Var. (TUR+Chemo : TUR Alone) % ±SD Epirubicin 153/325 99/317-26 36.7 Mitomycin C 129/221 95/206-13.2 26.6 Thiotepa 46/123 52/124 2.8 14.8 Pirarubicin 34/79 21/81-6.8 9.1 Total 362/748 267/728-43.2 87.3 (48.4%) (36.7%) 39% ±8 Reduction TUR+Chemo Better TUR Alone Better Test for Heterogeneity 2 =9.19, df=3: p=0.03 Treatment Effect: p=0.00000 TUR: Transurethral resection 1. Sylvester RJ et al. J Urol 2004; 171:2186-90. 5

Management of NMIBC Low Risk Group 1 Comparison of Guideline Recommendations for Low Risk Disease 24 EAU Guidelines (2017) TURBT Single immediate post operative instillation of chemotherapy (grade A) NCCN Guidelines (2017) TURBT Consider single immediate postoperative instillation of chemotherapy (category 2A), and/or FICBT Guidelines (2005) TURBT Single immediate post operative instillation of chemotherapy (grade A) AUA Guidelines (2016) TURBT Single immediate postoperative instillation of chemotherapy (moderate recommendation; grade B) FICBT: First International Consultation on Bladder Tumors NCCN: National Comprehensive Cancer Network TURBT: Transurethral resection of bladder tumour NMIBC: non-muscle invasive bladder cancer Brausi M et al. J Urol 2011; 186: 2158-67.

EAU Guidelines 2018

Meta-Analysis Who did not benefit from the instillation? Patients with a prior recurrence rate > 1 recurrence per year, Patients with a recurrence score > 5 Sylvester RJ. et al. Eur Urol 2016;69:231 244

European Gemcitabine Trial (2009) vs SWOG Trial (2018) 38.7* 37.1* * European Trial (2009)

It only works in low risk disease Major Problem Missing information about stage and grade at the time of instillation Hypothetical Case: Table 5 W eigh ts used to calculate th e recurren ce an d progression scores Factor Recurrence Progression Num ber of tum ors 0 Single 0 0 2 to 7 3 3 8 6 3 Tum or size < 3cm 0 3 0 3cm 3 3 Prior recurren ce rate Prim ary 0 0 1 rec/yr 2 2 > 1 rec/yr 4 2 0 on in pr of Single Primary 3 cm Pathology: T1 HG Tcategory Ta 0 1 0 T1 1 4 CIS No 0 0 Yes 1 6 Grade G1 0 0 G2 1 2 0 G3 2 5 Total score 0 17 0 23 Total points= 6 0 Fig O = pa

Continuous Bladder Irrigation with Saline

Effect of Post-operative Irrigation Nonrandomized comparison of 1592 patients Overall relative risk reduction 31% HR: 0.69 (95% CI, 0.59 0.88; p < 0.001) Single instillation: relative risk reduction 35% HR: 0.65; 95% CI, 0.58 0.74; p < 0.001. Adjustment for the randomized treatment and EORTC recurrence risk score post-op irrigation reduced the relative risk of recurrence by 21% HR: 0.79 (95% CI, 0.67 0.93; p = 0.004). Sylvester RJ. et al. Eur Urol 2016;69:231 244

Effect of Post-operative Irrigation

RCT with Con t Bladder Irrigation European Study Gem 2g (2009) Japanese Study MMC 30 mg (2017) Böhle A. et al. Eur Urol 2009;56:495-503 Onishi T. et al. BJU Int 2017; 119: 276 282

Overlay of Recurrence-free Survial Curves European (2009) vs SWOG (2018) data No Con t irrigation Gem (Europe) Con t irrigation Gem (SWOG)

PSI: No Effect on Progression Sylvester RJ. et al. Eur Urol 2016;69:231 244

Alarming Fact: Increased Mortality with PSI Increase in the risk of death by 26% with immediate instillation (HR: 1.26) Sylvester RJ. et al. Eur Urol 2016;69:231 244

Drugs Used for Instillation Sylvester RJ. et al. Eur Urol 2016;69:231 244

Argument Against Routine Use of PSI PSI is effective only in low risk patients Recurrences (if any) will be small papillary tumors (median size 3 mm) Sylvester RJ. Eur Urol 2016;69:231 244 (Strongly recommend a post hoc analysis of SWOG 2018 to find out the median size and grade of recurrences) These can be managed effectively by active surveillance or office fulguration Soloway MS. Urol Oncol. 2006;24:58-61 Effective reduction of recurrences by continuous bladder irrigation with saline post operatively

Significantly Innocent Looking

Significantly Mortal

Hippocratic Oath